Alpha-1
Alpha 1: Feel Better. Live Longer. Breathe Easier.
This customizable therapy aims to boost the levels of alpha-1 in the bloodstream and lungs of individuals diagnosed with emphysema. Alpha-1 Antitrypsin Deficiency Therapy allows patients to maintain stability over an extended period. By doing so, this therapy acts as a safeguard, shielding the delicate lung tissue from degradation and preventing further deterioration. This significant benefit promotes better respiratory health and helps preserve the overall well-being of A1 patients.
Who Can Benefit?
Patients who suffer from respiratory diseases such as COPD or emphysema.
Some of the potential benefits of Alpha-1 therapy include:
- Lung Health Improvement: By increasing the levels of functional alpha-1 antitrypsin protein, therapy can help protect lung tissues from damage caused by enzymes that break down lung tissue.
- Symptom Management: Alpha 1 therapy can alleviate respiratory symptoms such as shortness of breath, wheezing, coughing, and decreased exercise tolerance.
- Reduced Risk of Disease Progression: With proper treatment, individuals are less likely to experience rapid disease progression in their lungs, which could help them maintain lung function and overall health over time.
- Prevention of Liver Complications: In some cases, AATD can lead to liver diseases like cirrhosis. Therapy can help maintain healthy levels of alpha-1 antitrypsin protein, reducing the risk of liver complications.
- Stabilization of Enzyme Levels: Stabilizing alpha-1 antitrypsin protein levels in the blood can help control the imbalance between proteases (enzymes that break down proteins) and antiproteases (like alpha-1 antitrypsin) that contribute to lung tissue damage.
- Potential Reduction in Exacerbations: Fewer exacerbations of lung diseases mean reducing the frequency and severity of flare-ups that can worsen lung function.
